Latest Mentor Capital Inc. (MNTR) Headlines
WEALTHMAKERS.COM Issues Report on Mentor Capital
M2 - Mon Mar 10, 8:54AM CDT
March 10, 2014 / M2 PRESSWIRE / WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued a new research report today on Mentor Capital (OTC: MNTR). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price of $2.54 and the projected short squeeze price target of $19.59 per share.
Mentor Capital Catches Market Makers Selling 250% of Shares
Marketwire - Tue Feb 25, 11:50AM CST
Mentor Capital, Inc. (OTC Pink: MNTR) announces that BuyIns.Net has uncovered that Shorts have sold 5.5 Million of the 2.2 Million (sic.) Mentor Capital, Inc. shares in the float and available to trade. In response to this situation, Mentor Capital Inc.'s CEO, Chet Billingsley comments, "For 2014 we retained BuyIns.Net, who monitors all stock trades for illegal short selling activity, soon after 50% of our float suspiciously traded in two hours." According to his web site, BuyIns.Net founder, Tom Ronk, entered into a business partnership with former SEC Chairman, Harvey Pitt. They spearheaded the passage of Regulation SHO that, if followed, helps safeguard public companies from these sorts of short selling issues.
BUYINS.NET Issues Mentor Capital SqueezeTrigger Report
M2 - Tue Feb 25, 2:34AM CST
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Mentor Capital (OTC: MNTR) after releasing the latest short sale data through February 21, 2014. The total aggregate number of shares shorted since August 2009 is approximately 3.45 million shares. Approximately 41.09% of daily trading volume is short selling. The SqueezeTrigger price for all MNTR shares shorted is $1.53. A short squeeze has just begun as shares of MNTR closed above the $1.53 SqueezeTrigger price.
Mentor Capital Acquires 51% Stake in MicroCannaBiz, LLC
Business Wire - Thu Feb 20, 12:54PM CST
Mentor Capital, Inc. (OTC Markets: MNTR) announced today that it has acquired a 51% equity interest in MicroCannaBiz, LLC, which was recently formed to address the legal cannabis market by Financial Research Solutions, Inc., a media, microcap investment research and educational training company.
Mentor Capital Agrees to $2M Backing for Cannabis Advocacy Business
Business Wire - Mon Jan 27, 7:30AM CST
Mentor Capital, Inc. (OTC Markets: MNTR) announced that it has agreed to provide $2 Million in funding for The Cannabis Advocacy Machine. Mentor Capital CEO, Chester Billingsley, explains that behind any political initiative there is a commercial enterprise in the business of developing data and statistics, directing advertisement, and maintaining proprietary software systems. The Cannabis Advocacy Machine, a division of The Machine Corporation, is providing Moneyball-like direction and support that is key to that process for the legalization of cannabis across the country. "Signing a letter of intent for 20% of The Machine Corporation under the nationally experienced leadership of the first tier team with Joe Brezny, aims to accelerate the legislative initiatives critical to the lifting of marijuana prohibition, in what may be a surprisingly profitable manner."
Mentor Capital Cannabis Index Up 325% in First Three Weeks of 2014
Business Wire - Wed Jan 22, 10:25AM CST
Mentor Capital, Inc. (OTCMKTS:MNTR) reports that its proprietary Cannabis Index appreciated 325% during the first three weeks of 2014. The overall positive and profitable experience for marijuana based businesses and taxing authorities alike is thought to be a key driver in this sector-wide advance.
Mentor Capital Cancer Immunotherapy Index Up 97% in 2013
Business Wire - Tue Jan 21, 10:01AM CST
Mentor Capital, Inc. (OTCMKTS:MNTR) reports that its proprietary Cancer Immunotherapy Index appreciated 97.4% during 2013. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For the same 2013 annual period the biotech indices averaged a 54.8% gain.
Mentor Capital Says HempCon to be First Funded from New Public Cannabis Fund
Business Wire - Fri Jan 17, 12:40PM CST
Mentor Capital, Inc. (OTC Markets:MNTR) announced its first major acquisition for cannabis funding will be HempCon, Inc. That medical marijuana convention company is hosting hemp industry pioneers at the San Jose Convention Center January 17-19th. The agreement by principals and letter of intent outlines that HempCon, Inc. will receive $7.0 Million from Mentor Capital investors plus future public market appreciation for a 100% interest. Positioning HempCon to be the first to be funded by the first operating public cannabis fund of its kind should be wholly credited to savvy action by HempCon founder Edwin Kwong, who had already been approached by two other public companies, reports Mentor Capital CEO Chester Billingsley.
Mentor Capital Negotiates to Fund Eighteen Leading Cannabis Brands
Business Wire - Wed Nov 13, 9:43AM CST
Mentor Capital, Inc. (Pink Sheets:MNTR) reports that it has entered into negotiations to fund eighteen legal cannabis related companies. These companies are variously described in writing by their fellow CEO's as the "cream of the crop," "great, " "the best... I have ever seen" and that "their Cannabis Cup awards speak for themselves." While not every one of the CEO's in negotiations will finally join Mentor Capital, the offers are generally what management has already verbally agreed to.
Mentor Capital Cancer Immunotherapy Index Up 100% in 2013
Business Wire - Wed Oct 16, 7:03AM CDT
Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index appreciated 101.7% during the first three quarters of 2013. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For the same 2013 YTD period the biotech indices averaged a 46.0% gain.
Mentor Capital, Inc. Funds Completion of 12.5% Stock Buyback
Business Wire - Thu Sep 05, 1:56PM CDT
Mentor Capital, Inc. (OTCMKTS:MNTR) has deposited funds with its broker to complete the final tranche of its multi-year stock repurchase program. In 2008, Mentor Capital, Inc. committed to the repurchase of 12.5% of its then outstanding common stock and is positioned to wrap-up that stock buy-back now.
Mentor Capital Cancer Immunotherapy Index Gains 31% During First Half of 2013
Business Wire - Fri Jul 19, 12:49PM CDT
Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index appreciated 30.6% during the first half of 2013. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For the first half the biotech indices averaged a 34.5% gain.
Mentor Capital Cancer Immunotherapy Index Gains 32% YTD and Adds Second Generation Firms for 2013
Business Wire - Fri Mar 15, 11:51AM CDT
Mentor Capital, Inc. (Pink Sheets:MNTR) reports that for 2013 it has added Galena Biopharma Corporation (NASDAQ:GALE), NewLink Genetics Corporation (NASDAQ:NLNK), Vical Incorporated (NASDAQ:VICL) and Inovio Pharmaceuticals, Inc. (NYSE MKT:INO) to its proprietary Cancer Immunotherapy Index. The four firms and others in the Index represent the second generation immunotherapy knowledge that has evolved since 2009 when Mentor Capital first published.
Mentor Capital Telemedicine Investee Projects $1.0 Million Profit
Business Wire - Wed Mar 13, 11:40AM CDT
Mentor Capital, Inc. (OTC Markets: MNTR) announced that its portfolio company, Brighter Day Health, LLC, after a period of aggressive growth, reports it is ahead of budget and turning the corner to profitable operation. Brighter Day projects a before-tax profit of $1.0 Million for the next full fiscal year and $400,000 profit for the remainder of 2013. This positions the company for a planned 2015 exit seeking to match the market typical multiple of 12x-17x.
Mentor Capital Cancer Immunotherapy Index Posts 11% Annual Loss in 2012 and Adds Companies for 2013
Business Wire - Tue Feb 19, 6:55AM CST
Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index declined (-10.9%) during 2012. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For 2012 the biotech indices averaged a 32.7% gain. In comparison, during the first six months of 2012, the Dow, S&P 500 and NASDAQ Composite indices appreciated 5.90%, 16.61% and 15.89%, respectively.
WEALTHMAKERS.COM Issues Report on Mentor Capital
M2 - Mon Mar 10, 8:54AM CDT
March 10, 2014 / M2 PRESSWIRE / WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued a new research report today on Mentor Capital (OTC: MNTR). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price of $2.54 and the projected short squeeze price target of $19.59 per share.
Mentor Capital Catches Market Makers Selling 250% of Shares
Marketwire - Tue Feb 25, 11:50AM CST
Mentor Capital, Inc. (OTC Pink: MNTR) announces that BuyIns.Net has uncovered that Shorts have sold 5.5 Million of the 2.2 Million (sic.) Mentor Capital, Inc. shares in the float and available to trade. In response to this situation, Mentor Capital Inc.'s CEO, Chet Billingsley comments, "For 2014 we retained BuyIns.Net, who monitors all stock trades for illegal short selling activity, soon after 50% of our float suspiciously traded in two hours." According to his web site, BuyIns.Net founder, Tom Ronk, entered into a business partnership with former SEC Chairman, Harvey Pitt. They spearheaded the passage of Regulation SHO that, if followed, helps safeguard public companies from these sorts of short selling issues.
BUYINS.NET Issues Mentor Capital SqueezeTrigger Report
M2 - Tue Feb 25, 2:34AM CST
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Mentor Capital (OTC: MNTR) after releasing the latest short sale data through February 21, 2014. The total aggregate number of shares shorted since August 2009 is approximately 3.45 million shares. Approximately 41.09% of daily trading volume is short selling. The SqueezeTrigger price for all MNTR shares shorted is $1.53. A short squeeze has just begun as shares of MNTR closed above the $1.53 SqueezeTrigger price.
Mentor Capital Acquires 51% Stake in MicroCannaBiz, LLC
Business Wire - Thu Feb 20, 12:54PM CST
Mentor Capital, Inc. (OTC Markets: MNTR) announced today that it has acquired a 51% equity interest in MicroCannaBiz, LLC, which was recently formed to address the legal cannabis market by Financial Research Solutions, Inc., a media, microcap investment research and educational training company.
Mentor Capital Agrees to $2M Backing for Cannabis Advocacy Business
Business Wire - Mon Jan 27, 7:30AM CST
Mentor Capital, Inc. (OTC Markets: MNTR) announced that it has agreed to provide $2 Million in funding for The Cannabis Advocacy Machine. Mentor Capital CEO, Chester Billingsley, explains that behind any political initiative there is a commercial enterprise in the business of developing data and statistics, directing advertisement, and maintaining proprietary software systems. The Cannabis Advocacy Machine, a division of The Machine Corporation, is providing Moneyball-like direction and support that is key to that process for the legalization of cannabis across the country. "Signing a letter of intent for 20% of The Machine Corporation under the nationally experienced leadership of the first tier team with Joe Brezny, aims to accelerate the legislative initiatives critical to the lifting of marijuana prohibition, in what may be a surprisingly profitable manner."
Mentor Capital Cannabis Index Up 325% in First Three Weeks of 2014
Business Wire - Wed Jan 22, 10:25AM CST
Mentor Capital, Inc. (OTCMKTS:MNTR) reports that its proprietary Cannabis Index appreciated 325% during the first three weeks of 2014. The overall positive and profitable experience for marijuana based businesses and taxing authorities alike is thought to be a key driver in this sector-wide advance.
Mentor Capital Cancer Immunotherapy Index Up 97% in 2013
Business Wire - Tue Jan 21, 10:01AM CST
Mentor Capital, Inc. (OTCMKTS:MNTR) reports that its proprietary Cancer Immunotherapy Index appreciated 97.4% during 2013. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For the same 2013 annual period the biotech indices averaged a 54.8% gain.
Mentor Capital Says HempCon to be First Funded from New Public Cannabis Fund
Business Wire - Fri Jan 17, 12:40PM CST
Mentor Capital, Inc. (OTC Markets:MNTR) announced its first major acquisition for cannabis funding will be HempCon, Inc. That medical marijuana convention company is hosting hemp industry pioneers at the San Jose Convention Center January 17-19th. The agreement by principals and letter of intent outlines that HempCon, Inc. will receive $7.0 Million from Mentor Capital investors plus future public market appreciation for a 100% interest. Positioning HempCon to be the first to be funded by the first operating public cannabis fund of its kind should be wholly credited to savvy action by HempCon founder Edwin Kwong, who had already been approached by two other public companies, reports Mentor Capital CEO Chester Billingsley.
Mentor Capital Negotiates to Fund Eighteen Leading Cannabis Brands
Business Wire - Wed Nov 13, 9:43AM CST
Mentor Capital, Inc. (Pink Sheets:MNTR) reports that it has entered into negotiations to fund eighteen legal cannabis related companies. These companies are variously described in writing by their fellow CEO's as the "cream of the crop," "great, " "the best... I have ever seen" and that "their Cannabis Cup awards speak for themselves." While not every one of the CEO's in negotiations will finally join Mentor Capital, the offers are generally what management has already verbally agreed to.
Mentor Capital Cancer Immunotherapy Index Up 100% in 2013
Business Wire - Wed Oct 16, 7:03AM CDT
Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index appreciated 101.7% during the first three quarters of 2013. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For the same 2013 YTD period the biotech indices averaged a 46.0% gain.
Mentor Capital, Inc. Funds Completion of 12.5% Stock Buyback
Business Wire - Thu Sep 05, 1:56PM CDT
Mentor Capital, Inc. (OTCMKTS:MNTR) has deposited funds with its broker to complete the final tranche of its multi-year stock repurchase program. In 2008, Mentor Capital, Inc. committed to the repurchase of 12.5% of its then outstanding common stock and is positioned to wrap-up that stock buy-back now.
Mentor Capital Cancer Immunotherapy Index Gains 31% During First Half of 2013
Business Wire - Fri Jul 19, 12:49PM CDT
Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index appreciated 30.6% during the first half of 2013. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For the first half the biotech indices averaged a 34.5% gain.
Mentor Capital Cancer Immunotherapy Index Gains 32% YTD and Adds Second Generation Firms for 2013
Business Wire - Fri Mar 15, 11:51AM CDT
Mentor Capital, Inc. (Pink Sheets:MNTR) reports that for 2013 it has added Galena Biopharma Corporation (NASDAQ:GALE), NewLink Genetics Corporation (NASDAQ:NLNK), Vical Incorporated (NASDAQ:VICL) and Inovio Pharmaceuticals, Inc. (NYSE MKT:INO) to its proprietary Cancer Immunotherapy Index. The four firms and others in the Index represent the second generation immunotherapy knowledge that has evolved since 2009 when Mentor Capital first published.
Mentor Capital Telemedicine Investee Projects $1.0 Million Profit
Business Wire - Wed Mar 13, 11:40AM CDT
Mentor Capital, Inc. (OTC Markets: MNTR) announced that its portfolio company, Brighter Day Health, LLC, after a period of aggressive growth, reports it is ahead of budget and turning the corner to profitable operation. Brighter Day projects a before-tax profit of $1.0 Million for the next full fiscal year and $400,000 profit for the remainder of 2013. This positions the company for a planned 2015 exit seeking to match the market typical multiple of 12x-17x.
Mentor Capital Cancer Immunotherapy Index Posts 11% Annual Loss in 2012 and Adds Companies for 2013
Business Wire - Tue Feb 19, 6:55AM CST
Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index declined (-10.9%) during 2012. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For 2012 the biotech indices averaged a 32.7% gain. In comparison, during the first six months of 2012, the Dow, S&P 500 and NASDAQ Composite indices appreciated 5.90%, 16.61% and 15.89%, respectively.
